Literature DB >> 20646906

Results from the National Sepsis Practice Survey: use of drotrecogin α (activated) and other therapeutic decisions.

James M O'Brien1, Scott K Aberegg, Naeem A Ali, Gregory B Diette, Stanley Lemeshow.   

Abstract

PURPOSE: We sought to evaluate factors associated with choices about provided care for patients with septic shock, including the use of drotrecogin α (activated) (DAA).
MATERIALS AND METHODS: We administered a mail-based survey to a random sample of intensivists. Study vignettes presented patients with septic shock with identical severity of illness scores but different ages, body mass indices, and comorbidities. Respondents estimated outcomes and selected care beyond standardized initial care (eg, antibiotics) for each hypothetical patient.
RESULTS: For most vignettes (99.1%), respondents added care, most commonly low tidal volume ventilation (87.6%) and enteral nutrition (73.3%). Choosing to administer DAA was not associated with predictions about mortality or bleeding. Vignettes with early-stage lung cancer were less likely to receive DAA. Time since medical school graduation was also associated with lower odds of selecting DAA. Most respondents (52.6%) chose identical care for all 4 completed vignettes.
CONCLUSIONS: There was wide variability in the therapeutic choices of respondents. The use of DAA was not associated with perceived risk of mortality or bleeding, as recommended by consensus guidelines. Physicians appear to base treatment decisions in septic shock on a consistent pattern of practice rather than estimates of patient outcome.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20646906      PMCID: PMC2978258          DOI: 10.1016/j.jcrc.2010.04.010

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  34 in total

1.  Reported response rates to mailed physician questionnaires.

Authors:  S M Cummings; L A Savitz; T R Konrad
Journal:  Health Serv Res       Date:  2001-02       Impact factor: 3.402

Review 2.  Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.

Authors:  Peter Q Eichacker; Charles Natanson
Journal:  Crit Care Med       Date:  2003-01       Impact factor: 7.598

3.  Risks and benefits of activated protein C treatment for severe sepsis.

Authors:  H Shaw Warren; Anthony F Suffredini; Peter Q Eichacker; Robert S Munford
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

4.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

5.  The epidemiology of sepsis in the United States from 1979 through 2000.

Authors:  Greg S Martin; David M Mannino; Stephanie Eaton; Marc Moss
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

6.  Patient characteristics and ICU organizational factors that influence frequency of pulmonary artery catheterization.

Authors:  J Rapoport; D Teres; J Steingrub; T Higgins; W McGee; S Lemeshow
Journal:  JAMA       Date:  2000-05-17       Impact factor: 56.272

7.  Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study.

Authors:  Ricard Ferrer; Antonio Artigas; David Suarez; Eduardo Palencia; Mitchell M Levy; Angel Arenzana; Xose Luis Pérez; Josep-Maria Sirvent
Journal:  Am J Respir Crit Care Med       Date:  2009-08-20       Impact factor: 21.405

8.  Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Authors:  E Wesley Ely; Pierre-François Laterre; Derek C Angus; Jeffrey D Helterbrand; Howard Levy; Jean-François Dhainaut; Jean-Louis Vincent; William L Macias; Gordon R Bernard
Journal:  Crit Care Med       Date:  2003-01       Impact factor: 7.598

9.  Severe sepsis: variation in resource and therapeutic modality use among academic centers.

Authors:  D Tony Yu; Edgar Black; Kenneth E Sands; J Sanford Schwartz; Patricia L Hibberd; Paul S Graman; Paul N Lanken; Katherine L Kahn; David R Snydman; Jeffrey Parsonnet; Richard Moore; Richard Platt; David W Bates
Journal:  Crit Care       Date:  2003-03-17       Impact factor: 9.097

Review 10.  Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

Authors:  Gordon R Bernard; William L Macias; David E Joyce; Mark D Williams; Joan Bailey; Jean-Louis Vincent
Journal:  Crit Care       Date:  2003-02-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.